Culture Biosciences
PrivateLast Round
Series C
Dec 16, 2025
Est. Valuation
$1.71M
Total Funding Raised
$100.62M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Culture Biosciences operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series C round in December 2025.
Culture Biosciences is a biotechnology company that develops automated bioreactors and cloud-native software to optimize manufacturing processes for sensitive cell cultures and high cell density fermentation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Cloud Infrastructure
Business Model
B2B
Customer Profile
Services & Consulting, Hardware Sales, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Culture Biosciences Comparables
Compare Culture Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mytos | 79% | |
| QB Systems | 78% | |
| Donaldson Company | 77% |
For institutional investors. Book with your work email.
Culture Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Dec 16, 2025 | ||||
| Series B | Oct 14, 2021 | ||||
| Series A | Mar 4, 2020 | ||||
| Seed | Feb 12, 2019 | ||||
| Accelerator | Jan 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Culture Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series A, Series B, Series C, Seed |
| Refactor Capital | Seed |
| The Production Board | Series A, Series B |
| Synthesis Capital | Series B, Series C |
| Cultivian Sandbox Ventures | Series B, Series C, Series A |
| Craft Ventures | Series B |
| Northpond Ventures | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors grew 30% MoM, reaching 10.1K.
- Jul 27, 2026
Monthly visitors increased 36% MoM.
For institutional investors. Book with your work email.
Culture Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Culture Biosciences's valuation, stock price, and market status.
Is Culture Biosciences a public or private company?
Culture Biosciences is a private company.
What is the current stock price of Culture Biosciences?
Culture Biosciences is a private company, so its shares have no public market price. Caplight tracks Culture Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Culture Biosciences worth (valuation)?
Culture Biosciences's valuation is estimated at $1.7M based on funding round data.
Can I buy Culture Biosciences stock?
Culture Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Culture Biosciences's last funding round?
Culture Biosciences's most recent funding round was Series C on December 16, 2025.
Who are the main investors in Culture Biosciences?
Key investors in Culture Biosciences include S32, Cultivian Sandbox Ventures, Northpond Ventures, Y Combinator, Northpond Ventures.
Will Culture Biosciences IPO soon?
No public IPO plans have been announced for Culture Biosciences.
How can I track Culture Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Culture Biosciences's shares on secondary markets.